COSMIC-311 Final Analysis: Phase III Trial of Cabozantinib vs Placebo in Radioiodine-Refractory Differentiated Thyroid Cancer After VEGFR TKI

September 16-21, 2021; Virtual
In this final analysis of the landmark COSMIC-311 trial, cabozantinib maintained a significant PFS benefit vs placebo in patients with radioiodine-refractory/-ineligible differentiated thyroid cancer after prior VEGFR TKI therapy.
Format: Microsoft PowerPoint (.ppt)
File Size: 242 KB
Released: September 29, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Exelixis, Inc.
Ipsen Biopharmaceuticals, Inc.

Related Content

Dr Evan J. Lipson shares expert insights on the safety and efficacy of anti-LAG-3 immunotherapies in this webcast from Clinical Care Options (CCO)

Evan J. Lipson, MD Tian Zhang, MD, MHS Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: April 20, 2022 Expired: April 19, 2023

Downloadable slideset from a workshop series from Clinical Care Options (CCO) on the management of NTRK and RET-altered malignancies.

Alexander Drilon, MD Thomas Stinchcombe, MD Released: April 12, 2022

Downloadable slideset on targeting LAG-3 in multiple tumor types and evidence on recently approved LAG-3 therapy, relatlimab, from Clinical Care Options (CCO)

Evan J. Lipson, MD Tian Zhang, MD, MHS Released: March 23, 2022

Downloadable PDF resource on LAG-3, safety and efficacy of approved anti-LAG-3 agent relatlimab, and clinical trial spotlight from Clinical Care Options (CCO)

Krista M. Rubin, MS, RN, FNP-BC Released: March 23, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings